UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

~~Pursuant~~Date toof ~~Section~~Report 13(Date orof ~~15(d~~earliest event reported): March of20, ~~the~~2024

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2024 (February 29, 2024)

VERDE BIO HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada	000-54524	30-0678378
(State or other Jurisdiction	(Commission	(IRS Employer
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
of Incorporation)	File Number)	Identification No.)

POP.O. Box 67

Jacksboro, Texas 76458

(Address of Principal Executive Offices) ~~(Zip Code)~~

(972) 217-4080

(Registrant’s ~~telephone~~Telephone ~~number~~Number, ~~including~~Including Area ~~area code~~Code)

~~Securities~~Check ~~registered~~the ~~pursuant~~appropriate box below if the Form 8-K filing is intended to ~~Section~~simultaneously ~~12(b)~~satisfy the filing obligation of the ~~Act~~registrant under any of the following provisions (see General Instruction A.2. below):

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, $0.001 par value		VBHI		OTC Pink

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4I under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1Securities registered pursuant to Section 12(b) of the Act:

~~Item~~Title ~~4.01.Changes~~of ineach ~~Registrant’~~class Trading Symbol(s) ~~Certifying~~Name ~~Accountant.~~of each exchange on which registered COMMON SHARES VBHI OTC PINK

OnItem ~~February 29, 2024, the Board of Directors (the “Board”) of Verde Bio Holdings, Inc~~2.,01 aAcquisition ~~Nevada corporation (the “Company”, “we”, “us”~~ or ~~“our”),~~Disposition ~~approved the engagement~~ of Fruci & Associates II, PLLC (“Fruci”), as our independent registered public accounting firm, effective immediately. During the fiscal years ended April 30, 2022 and April 30, 2023, and the subsequent interim period through February 29, 2024, we did not, nor did anyone on our behalf, consult with Fruci with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial statements, and no written report or oral advice was provided to us that Fruci concluded was an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issue or (b) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).Assets

~~Contemporaneous~~On ~~with~~March ~~the Board’s determination to engage Fruci~~20, ~~Sadler~~2024, ~~Gibb~~Verde &Bio ~~Associates~~Holdings, ~~LLC~~Inc. (the “~~Sadler~~Company”) announced ~~resigned~~that asit ~~our~~had ~~independent~~closed ~~registered public accounting firm, effective immediately. The reports of Sadler~~ on ~~our~~a ~~financial~~transaction ~~statements for each~~ of ~~the~~certain ~~two~~mineral ~~fiscal years ended April 30, 2022,~~ and ~~April~~royalty ~~30,~~interests ~~2023,~~(“Acquisition”) ~~did~~with ~~not contain an adverse opinion or~~ a ~~disclaimer~~private ofbuyer whereby ~~opinion,~~the ~~nor~~Company ~~were~~divested ~~they~~100% ~~qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audits~~ of ~~our~~certain ~~financial~~mineral ~~statements for the fiscal years ended April 30, 2022,~~ and ~~April~~oil ~~30, 2023,~~ and ~~during~~gas ~~the~~royalty ~~subsequent~~interests ~~interim~~for ~~period through February 29~~$272,000 ~~2024, there were no “disagreements” (as that term is defined~~ in ~~Item~~cash, ~~304~~(~~a)(1)(iv)~~“Purchase ~~of Regulation S-K and related instructions~~Price”). The ~~between~~acquisition usclosed ~~and Sadler~~ on ~~any~~March ~~matter of accounting principles or practices~~20, ~~financial statement disclosure or auditing scope or procedures which~~2024, ifwith ~~not resolved to~~ the ~~satisfaction~~effective ofdate ~~Sadler, would have caused Sadler to make reference to the subject matter~~ of the ~~disagreement~~acquisitions inMarch ~~their report. During the fiscal years ended April 30~~1, ~~2022 and April 30, 2023 and the subsequent interim period through February 29,~~ 2024~~, there were no “reportable events” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K)~~.

WeA ~~provided~~form ~~Sadler with a copy~~ of the ~~disclosures~~Purchase ~~contained~~Agreement in this Current Report on Form 8-K and requested that Sadler furnish us with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained herein. A copy of Sadler’s letter, dated February 29, 2024, is filed as Exhibit 16 10.11to to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

~~(d)~~ Exhibits. The following exhibits are being filed herewith:

See the Exhibit Index below, which is incorporated by reference herein.

Exhibit Number		Description of Exhibits

10.1		Purchase and Sale Agreement

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibit No.		Description
16.1		Letter of Sadler, Gibb & Associates, LLC, dated February 29, 2024, to the Securities and Exchange Commission.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this ~~report~~Report to be signed on its behalf by the undersigned , hereunto duly authorized, on the 25th day of March, 2024.

	Verde Bio Holdings, Inc.
Date: March 1, 2024	By:	/s/ Scott Cox
		Scott Cox
		President

VERDE BIO HOLDINGS, INC.

By:	/s/ Scott A. Cox
	Name:	Scott A. Cox
	Title:	Chief Executive Officer

Exhibit Index to Current Report on Form 8-K

Exhibit Number		Description of Exhibits

10.1		Purchase and Sale Agreement

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filing Compare · VERDE BIO HOLDINGS, INC.